NeuroEndocrine Cancer Australia

NeuroEndocrine Cancer Australia (NECA) welcomes the Pharmaceutical Benefits Scheme (PBS) listing of Selpercatinib (Retevmo) for eligible Australians living with advanced or metastatic medullary thyroid cancer (MTC) with RET mutation effective from 1 August 2026. Medullary thyroid cancer is a rare neuroendocrine cancer arising from the parafollicular (C) cells of the thyroid. App...

NECA recently joined the second Rare Conversations event, hosted by the Patient Voice Initiative and Alexion, to discuss PBS reform for rare disease treatments. It was a valuable opportunity to advocate on behalf of the NET community and connect with fellow rare disease organisations working towards greater access and equity. Invited to be on the […]

Big News: We’re a Top 5 Finalist for the 2026 Patients’ Choice Awards! We’re beyond excited to share some fantastic news — NeuroEndocrine Cancer Australia has been named a Top 5 Finalist for the Outstanding Cancer & Rare Disease Organisation Award at the 2026 Patients’ Choice Awards! This recognition means so much to us. Organisations […]

Have You Used Our NET Nurse, Counsellor or Dietitian Services This Year? We’d Love Your Feedback If you, a family member, or someone you care for has had a call with one of our NET Nurses, Counsellor or Dietitian at any point this year, we’d really appreciate a few minutes of your time. Where appropriate, […]